R&D Alzheimer's research is moving toward more selective targets As we mark World Alzheimer’s Day, it is worth reflecting on the progress made in recent years.
R&D Alzheimer’s research: Cutting through the noise to find the ... A closer look at how clinical trials for Alzheimer’s have evolved and what this means for patients and sites, with Medidata and Cogstate.
News Click claims FDA okay for first-in-class schizophrenia DTx Click Therapeutics has won the first-ever FDA approval for a treatment for the negative symptoms of schizophrenia, a DTx called Motivista.
Digital Sponsored Discover a new era of healthcare panel engagement: Grounded ... A new webinar from Konovo will address some of the critical topics impacting today’s healthcare market research industry.
